191 related articles for article (PubMed ID: 38139172)
1. Epigenomic Profiling Advises Therapeutic Potential of Leukotriene Receptor Inhibitors for a Subset of Triple-Negative Breast Tumors.
Kalinkin AI; Sigin VO; Kuznetsova EB; Ignatova EO; Vinogradov II; Vinogradov MI; Vinogradov IY; Zaletaev DV; Nemtsova MV; Kutsev SI; Tanas AS; Strelnikov VV
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139172
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic silencing of triple negative breast cancer hallmarks by Withaferin A.
Szarc Vel Szic K; Declerck K; Crans RAJ; Diddens J; Scherf DB; Gerhäuser C; Vanden Berghe W
Oncotarget; 2017 Jun; 8(25):40434-40453. PubMed ID: 28467815
[TBL] [Abstract][Full Text] [Related]
3. Leukotriene receptor expression in esophageal squamous cell cancer and non-transformed esophageal epithelium: a matched case control study.
Venerito M; Helmke C; Jechorek D; Wex T; Rosania R; Antweiler K; Weigt J; Malfertheiner P
BMC Gastroenterol; 2016 Jul; 16(1):85. PubMed ID: 27475906
[TBL] [Abstract][Full Text] [Related]
4. ADAM12 is A Potential Therapeutic Target Regulated by Hypomethylation in Triple-Negative Breast Cancer.
Mendaza S; Ulazia-Garmendia A; Monreal-Santesteban I; Córdoba A; Azúa YR; Aguiar B; Beloqui R; Armendáriz P; Arriola M; Martín-Sánchez E; Guerrero-Setas D
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019179
[TBL] [Abstract][Full Text] [Related]
5. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
6. Hypomethylation of the MMP7 promoter and increased expression of MMP7 distinguishes the basal-like breast cancer subtype from other triple-negative tumors.
Sizemore ST; Sizemore GM; Booth CN; Thompson CL; Silverman P; Bebek G; Abdul-Karim FW; Avril S; Keri RA
Breast Cancer Res Treat; 2014 Jul; 146(1):25-40. PubMed ID: 24847890
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer.
Kagara N; Huynh KT; Kuo C; Okano H; Sim MS; Elashoff D; Chong K; Giuliano AE; Hoon DS
Am J Pathol; 2012 Jul; 181(1):257-67. PubMed ID: 22626806
[TBL] [Abstract][Full Text] [Related]
8. Endocan as a prognostic biomarker of triple-negative breast cancer.
Sagara A; Igarashi K; Otsuka M; Kodama A; Yamashita M; Sugiura R; Karasawa T; Arakawa K; Narita M; Kuzumaki N; Narita M; Kato Y
Breast Cancer Res Treat; 2017 Jan; 161(2):269-278. PubMed ID: 27888420
[TBL] [Abstract][Full Text] [Related]
9. Reduction of nuclear Y654-p-β-catenin expression through SH3GL2-meditated downregulation of EGFR in chemotolerance TNBC: Clinical and prognostic importance.
Islam MS; Dasgupta H; Basu M; Roy A; Alam N; Roychoudhury S; Kumar Panda C
J Cell Physiol; 2020 Nov; 235(11):8114-8128. PubMed ID: 31960967
[TBL] [Abstract][Full Text] [Related]
10. Subtype-specific overexpression of the Rac-GEF P-REX1 in breast cancer is associated with promoter hypomethylation.
Barrio-Real L; Benedetti LG; Engel N; Tu Y; Cho S; Sukumar S; Kazanietz MG
Breast Cancer Res; 2014 Sep; 16(5):441. PubMed ID: 25248717
[TBL] [Abstract][Full Text] [Related]
11. The frequency of CpG and non-CpG methylation of Notch3 gene promoter determines its expression levels in breast cancer cells.
Xiao W; Liu X; Niu X; Li C; Guo Y; Tan J; Xiong W; Fan L; Li Y
Exp Cell Res; 2020 Jan; 386(2):111743. PubMed ID: 31770532
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value and immune landscapes of TERT promoter methylation in triple negative breast cancer.
Lin F; Huang J; Zhu W; Jiang T; Guo J; Xia W; Chen M; Guo L; Deng W; Lin H
Front Immunol; 2023; 14():1218987. PubMed ID: 37575241
[TBL] [Abstract][Full Text] [Related]
13. TET1-Mediated Hypomethylation Activates Oncogenic Signaling in Triple-Negative Breast Cancer.
Good CR; Panjarian S; Kelly AD; Madzo J; Patel B; Jelinek J; Issa JJ
Cancer Res; 2018 Aug; 78(15):4126-4137. PubMed ID: 29891505
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers.
Ward AK; Mellor P; Smith SE; Kendall S; Just NA; Vizeacoumar FS; Sarker S; Phillips Z; Alvi R; Saxena A; Vizeacoumar FJ; Carlsen SA; Anderson DH
Breast Cancer Res; 2016 Jan; 18(1):12. PubMed ID: 26810754
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological Features of Triple-Negative Breast Cancer Epigenetic Subtypes.
DiNome ML; Orozco JIJ; Matsuba C; Manughian-Peter AO; Ensenyat-Mendez M; Chang SC; Jalas JR; Salomon MP; Marzese DM
Ann Surg Oncol; 2019 Oct; 26(10):3344-3353. PubMed ID: 31342401
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of beta-catenin in chemo-tolerant TNBC through changes in receptor and antagonist profiles of the WNT pathway: Clinical and prognostic implications.
Islam S; Dasgupta H; Basu M; Roy A; Alam N; Roychoudhury S; Panda CK
Cell Oncol (Dordr); 2020 Aug; 43(4):725-741. PubMed ID: 32430683
[TBL] [Abstract][Full Text] [Related]
17. Identification of DDIT4 as a potential prognostic marker associated with chemotherapeutic and immunotherapeutic response in triple-negative breast cancer.
Chen X; Li Z; Liang M; Zhang Z; Zhu D; Lin B; Zhou R; Lu Y
World J Surg Oncol; 2023 Jun; 21(1):194. PubMed ID: 37391802
[TBL] [Abstract][Full Text] [Related]
18. Multiomics analysis reveals CT83 is the most specific gene for triple negative breast cancer and its hypomethylation is oncogenic in breast cancer.
Chen C; Gao D; Huo J; Qu R; Guo Y; Hu X; Luo L
Sci Rep; 2021 Jun; 11(1):12172. PubMed ID: 34108519
[TBL] [Abstract][Full Text] [Related]
19. Expression of CD22 in Triple-Negative Breast Cancer: A Novel Prognostic Biomarker and Potential Target for CAR Therapy.
Zaib T; Cheng K; Liu T; Mei R; Liu Q; Zhou X; He L; Rashid H; Xie Q; Khan H; Xu Y; Sun P; Wu J
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768478
[TBL] [Abstract][Full Text] [Related]
20. Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression.
Anbalagan M; Sheng M; Fleischer B; Zhang Y; Gao Y; Hoang V; Matossian M; Burks HE; Burow ME; Collins-Burow BM; Hangauer D; Rowan BG
Mol Cancer Res; 2017 Nov; 15(11):1491-1502. PubMed ID: 28751463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]